Live Breaking News & Updates on Argeted therapy

Stay informed with the latest breaking news from Argeted therapy on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Argeted therapy and stay connected to the pulse of your community

Targeted drug, radiotherapy could prolong life of liver cancer patients with resistance to immunotherapy, Hong Kong studies find

Chinese University researchers say patients in trial took oral targeted therapy once a day and underwent scans every six weeks.

Hong-kong , South-korea , China , Chinese , Stephen-chan , Chinese-university , Landon-chan-long , Liver-cancer , Mmunotherapy , Argeted-therapy , Adiotherapy , Abozantinib

What's old is new again in the fight against cancer

What's old is new again in the fight against cancer
beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.

Astrazeneca , Pfizer , Street-journal , Meta-keywords-drugmakers , Ancer , Argeted-therapy , Ntibody-drug-conjugates , Dcs , Da , Echnology , Nvestments

"PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors agai" by Jay R. Perry, Benjamin Genenger et al.

Cutaneous squamous cell carcinoma (cSCC) is a very common skin malignancy with poor prognosis for patients with locally advanced or metastatic cSCC (mcSCC). PI3K/AKT/mTOR and cell cycle signalling pathways are often dysregulated in mcSCC. A combination drug approach has been theorised to overcome the underwhelming clinical performance of targeted inhibitors as single agents. This study investigates the potential of targeted inhibition of the p110α−subunit of PI3K with PIK-75 or BGT226 (P13Ki), and of CDK1/2/5/9 with dinaciclib (CDKi) as single agents and in combination. The patient−derived mcSCC cell lines, UW-CSCC1 and UW-CSCC2, were used to assess cell viability, migration, cell signalling, cell cycle distribution, and apoptosis. PIK-75, BGT226, and dinaciclib exhibited strong cytotoxic potency as single agents. Notably, the non-malignant HaCaT cell line was unaffected. In 2D cultures, PIK-75 synergistically enhanced the cytotoxic effects of dinaciclib in UW-CSCC2, but not UW-CSCC1. Interestingly, this pattern was reversed in 3D spheroid models. Despite the combination of PIK-75 and dinaciclib resulting in an increase in cell cycle arrest and apoptosis, and reduced cell motility, these differences were largely negligible compared to their single-agent counterpart. The differential responses between the cell lines correlated with driver gene mutation profiles. These findings suggest that personalised medicine approaches targeting PI3K and CDK pathways in combination may yield some benefit for mcSCC, and that more complex 3D models should be considered for drug responsiveness studies in this disease.

Cdk1-2-5-9 , Ombination-therapy , Scc , Utaneous-squamous-cell-carcinoma , Yclin-dependent-kinase , Inaciclib , Etastasis , Hosphoinositid-3-kinase , I3k , Ik-75 , Argeted-therapy

Drugmakers turn to class of cancer drugs to fuel growth in 2024

Drugmakers turn to class of cancer drugs to fuel growth in 2024
beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.

Andy-hsieh , Ambrx-biopharma , Wiliam-blair-company , Johnson , Pfizer , Wiliam-blair , Meta-keywords-drugmakers , Ancer-drugs , Ntibody-drug-conjugates , Rowth , Argeted-therapy , Da

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and only selective

China , United-states , Cairo , Al-qahirah , Egypt , Macau , Cancer-institute , Belgium , Osaka , Japan , Hong-kong , Australia

Promising Paths for Longevity Illumined!

Potential for future therapies to enhance healthy aging lies in drugs that release minute quantities of hydrogen sulfide (H2S).

Healthy-aging , Future-therapy , Rugs , Uture-therapy , Ydrogen-sulfide , Argeted-therapy ,

Role of nuclear medicine in cancer care: From timely diagnosis, detection of potential relapses, to better treatment planning

"Nuclear medicine has been available in India for the last 50 years. Whereas, PRRT therapies got US FDA approval last year," says Dr Sameer Sonar, Fellow, Harvard Medical School, USA, Group Director – Nuclear Medicine, PET CT Theranostics,Ruby Hall Clinic Group Hospitals

India , Mumbai , Maharashtra , United-states , Australia , Karuna-luthra , G-vamshi-krishna-reddy , Kokilaben-dhirubhai-ambani , Atomic-energy-regulatory-board , Oncology-services , India-institute-of-medical-sciences , Bhabha-atomic-research-centre

At Fox Chase Cancer Center aims to destroy tumors with NanoKnife electricity but preserve the prostate

NanoKnife, Fox Chase Cancer Center is treating prostate cancer with targeted therapy that treats malignancy without damaging healthy tissue.

Australia , Pennsylvania , United-states , Fox-chase-cancer-center , Fox-chase , Andres-correa , David-chen , Fox-chase-cancer , Prostate-cancer , Ox-chase-cancer-center , Argeted-therapy , Imely

Role of Liquid Biopsy in the Management of Cancer Shared by Art of Healing Cancer

Gurgaon (Haryana) [India], March 14 (ANI/BusinessWire India): Art of Healing Cancer, a leading cancer care provider in India, is pleased to share information on the role of liquid biopsy in the management of cancer. This technique is revolutionizing cancer care by providing a non-invasive and more accurate way of detecting cancer and monitoring its progression. Liquid Biopsy in layman's terms is detecting cancer cells or cancer material from a simple blood sample rather than putting needles in the body organs to get tissues/cells for assessment of cancer cells. Dr Mandeep Singh, Chief mentor & Lead oncologist at Art of Healing Cancer, explains Liquid Biopsy is either in form of Circulating tumor DNA (CtDNA) i.e. genetic material that is released by tumor cells into the bloodstream, while Circulating Tumor Cells (CTCs) are whole tumor cells that have detached from the primary tumor and entered the bloodstream. It is a less invasive and simpler procedure. It has a proven role in prognostication i.e. it can predict cancer recurrence before it shows in imaging such as PET CT scan. For e.g: - 1. A patient who has completed his/her treatment of cancer in form of surgery, chemotherapy and radiation can be followed up by timely blood samples for liquid biopsy and it can ring alarm bells at initial stages so that timely intervention can be done. 2. A patient with advanced-stage cancer is being treated with newer modalities like immunotherapy, cancer vaccines, neutraceuticals, etc can monitor the treatment response with liquid biopsy. Certain uses of Liquid Biopsy which can be game changing in the field of cancer treatment: 1. The Circulating Tumor cells can be isolated from bloodstream. These cells can then be grown in the lab in form of 3D cell culture/organoid; viability assays to assess the effectiveness of chemotherapy, targeted therapy, immunotherapy, natural supplements (ayurveda), etc. The CTC is now believed to be the most representative of disease process as it will have changes present at the primary site as well as whatever new changes the cancer has acquired during its spread 2. Genomic analysis of CtDNA or from the DNA / RNA of CTC helps to understand the changes which caused cancer, the pathways that are active or downregulated which are causing the spread of disease so that they can be targeted by conventional chemotherapy, immunotherapy, targeted therapy or natural supplements to achieve better cancer control. CtDNA fragements can represent the complete changes or may represent only some part, therefore the preferred genomic analysis is from the DNA / RNA of CTCs. The use of Liquid biopsy for early detection of cancer or cancer screening has a great future but at present, it has limitations and needs to be tested. It can be used for high risk individuals but not for mass population based screening. Art of Healing Cancer has collaborated with RGCC Labs Greece, a pioneer in the field of liquid biopsy, to offer its services in India. RGCC Labs uses advanced technology and state-of-the-art equipment to analyze CtDNA and CTCs, providing clinicians with accurate and reliable results. "We are excited to offer our patients the latest technology in liquid biopsy, which can help us personalise their cancer treatment and improve their outcomes," said Arpan Talwar, Founder, Art of Healing Cancer. "Through our collaboration with RGCC Labs Greece, we can provide our patients with access to cutting-edge diagnostic tools and treatments." Liquid biopsy is an exciting new field in cancer care, and Art of Healing Cancer is committed to offering its patients the best possible care through innovative and personalised treatment options. This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

Greece , India , Gurgaon-haryana , Mandeep-singh , Arpan-talwar , Businesswire-india , Healing-cancer , Liquid-biopsy , Circulating-tumor-cells , Circulating-tumor , Gurgaon-haryana-india-

Decoding Cancer Cell Pathway to Unlock Effective Therapies

Scientists have understood the pathway of cell metastases that can be applied to targeted therapies

Chicago , Illinois , United-states , Decoding-cancer-cell-pathway , Unlock-effective , Cancer-cell-pathway , Cancer , Etastases , Argeted-therapy , Ancer-spread , Ncology